The Alzheimer’s Association has granted 3$ million to Longeveron, a biotechnology company focused on treating age-related diseases, to fund their Phase I clinical trial, which utilizes mesenchymal stem cells to treat the chronic inflammation that has been associated with the development of Alzheimer’s disease. Mesenchymal stem cells, known for their immunomodulatory and anti-inflammatory properties, are ideal candidates to treat areas of inflammation, as other studies have already successfully shown their efficacy in regulating this condition.
Topics: treating Alzheimer's
In a Phase II clinical trial, researchers are using autologous (the patients’ own) mesenchymal stem cells to treat Alzheimer’s disease. According to the Centers for Disease Control (CDC) 5.7 million Americans are currently suffering from Alzheimer’s [with approximately 5.5 million over the age of 65 and approximately 220k under 65 experiencing early onset Alzheimer’s] with the number expected to triple by 2060. Additionally, the disease is one of the top 10 leading causes of death in U.S. adults; and while incidents of other common ailments like heart disease and cancer are decreasing, Alzheimer’s is on the rise.
Researchers at Rutgers University have created a bio-degradable scaffold that could overcome the biggest hurdle in stem cell treatments, which is cell survival and delivery. In order for a treatment to be effective, the stem cells must reach the designated site and remain there while they work. "Our enhanced stem cell transplantation approach is an innovative potential solution," comments Professor Ki Bum Lee, senior author of the study.
Researchers at the Massachusetts General Hospital are advancing Alzheimer’s research by creating lab grown models of affected neurons, which will allow for a vastly improved and nuanced understanding of the inner-workings of Alzheimer’s. Alzheimer’s is a neurological disorder that is difficult to diagnose and currently, can only be confirmed during a post-mortem autopsy, which usually reveals the neural inflammation that is believed to be the cause of most of the symptoms leading to the ultimate loss of memory and basic skills. Using stem cells, the researchers were able to grow neurons that exhibit both neuroinflammation and the indicative tangles and plaques of Alzheimer’s. This major breakthrough should enable the development of more targeted, effective treatments - and possibly a cure for Alzheimer’s, which currently affects millions of people worldwide and has no effective treatment options.
Researchers at UC Davis have created lab-grown brain organoids that are complex and vascularized, dramatically furthering research for brain disorders. Given that the human brain is one of the most complex anatomical structures and researchers are still discovering new functions and neuronal pathways, having brain organoids in vitro greatly expedites this research. When several small brain organoids joined together, researchers observed nerve impulses among the structures, signifying cellular communication that resembles that of fully-grown human brains. In a recent development, these organoids have vascularized and have brought researchers one step closer to both understanding neurological disorders, as well as helping patients replace damaged neurons from conditions like strokes, Alzheimer’s etc.